Navigation Links
Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
Date:5/15/2012

d a variable risk of transformation to acute myeloid leukemia.  It is estimated that MDS affects approximately 300,000 people worldwide.  According to the American Cancer Society, 10,000–20,000 new cases of MDS are diagnosed each year in the United States, with survival rates ranging from six months to six years.  MDS patients often require multiple blood transfusions to manage their disease.

Telintra has a novel mechanism of action that inhibits an enzyme called glutathione S-transferase P1-1, which leads to activation of Jun kinase, a key regulator of cellular growth and differentiation of blood precursor cells; this mechanism induces cancer cell death, or apoptosis, in human leukemia cell lines. Telintra is also being evaluated in a Phase 2 clinical trial in Revlimid refractory and resistant deletion 5q MDS patients and a Phase 2b clinical trial in non-deletion 5q MDS patients.  Additional information about Telintra is available at www.telik.com.

About Telik, Inc.

Telik, Inc. of Palo Alto, CA, is a clinical-stage drug development company focused on discovering and developing small-molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome, followed by Telcyta®, a cancer-activated prodrug for the treatment of a variety of cancers.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small-molecule drug candidates.

This press release contains "forward-looking" statements regarding the future development of Telintra, the safety and effectiveness of Telintra in treating MDS, whether Telintra treatment results in hematologic improvement in patients with MDS, whether Telintra reduces the need for, or offer
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Regains Compliance With Minimum Bid Price Requirement
2. Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance
3. Telik Announces Presentation and Webcast at 14th Annual BIO CEO & Investor Conference
4. Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology
5. Telik Announces Third Quarter 2011 Financial Results
6. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
7. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
9. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
10. Telik Announces First Quarter 2011 Financial Results
11. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... , Chief Executive Officer, will be presenting at the 26 ... York Palace Hotel in New York . ... at 2:00 PM ET. In addition, Mr. Krakauer and ... for separate one-on-one meetings during the day. ...
(Date:11/21/2014)... -- Depomed, Inc. (NASDAQ: DEPO ) today announced that ... Annual Healthcare Conference in New York City . ... for 8:00 am EST (5:00 am PST) on Tuesday December 2, ... accessed via the Investor Relations page of the Depomed website at ... for 30 days on the company,s website. About ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2
... April 11, 2012  Blue Mountain Hospital has used an electronic ... announced plans to swap out its original technology with an ... "We were lucky to start out as a ... are using simply is not meeting all of our needs," ...
... BAY, Wis., April 11, 2012   IOD Incorporated™, ... health systems, and physician practices, today announced its response ... a proposed rule to delay ICD-10 from October 1, ... http://photos.prnewswire.com/prnh/20111207/CG18689LOGO ) According to HHS regulations ...
Cached Medicine Technology:Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 2Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 3IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 2IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 3
(Date:11/22/2014)... Nov. 22, 2014 (HealthDay News) -- The wide variety ... pose a threat for people with food allergies, an ... are so many types of food allergies that it ... the holidays," Dr. Guha Krishnaswamy, director of allergy and ... in a hospital news release. "If you know ...
(Date:11/22/2014)... Recently, UWDress.com is gratified to introduce its new ... addition, the company has also offered an attracting discount ... online supplier of wedding dresses, UWDress.com is good at ... wedding guest gowns are provided over 20 colors, which ... selection is famous for high quality. Therefore, its sales ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Developers and plugin ... new plugin entitled FCPX 3D Model bringing the impossible to ... Model allows users to add obj files to FCPX enabling ... Studios. “Blurring the line between professional and armature, FCPX 3D ... Pixel Film Studios allows Final Cut Pro X users to ...
(Date:11/22/2014)... (HealthDay News) -- Many young people consider hookahs a ... study finds fumes from the water pipes contain the ... increased risk for leukemia in prior research, according to ... Cancer Epidemiology, Biomarkers & Prevention . "In ... not a safe alternative to smoking other forms of ...
(Date:11/21/2014)... CT (PRWEB) November 21, 2014 CRN ... a veteran radio industry sales professional to its award-winning ... brings 30 years of leadership and sales experience to ... and assume the title of Director of Strategy and ... Development, Robert O’Mara. , Heinemann will handle a wide ...
Breaking Medicine News(10 mins):Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2Health News:Hookahs Deliver Toxic Benzene in Every Puff, Study Shows 2Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2
... WASHINGTON, Oct. 1 Today the Senate ... secured by,Senator John Kerry (D-Mass.) to extend the ... to increase the transition and,commercialization of products developed ... the thousands of firms that participate in the,program ...
... Board Chair, Named Executive ... Chairman, ... ), a biopharmaceutical company focused on the discovery,and development of drugs for ... that Corey Goodman,Ph.D., will step down today as President and Chief Executive ...
... SAN DIEGO, Oct. 1 Amylin Pharmaceuticals,Inc. ... the U.S. Food and Drug,Administration (FDA) has ... pen-injector devices for administering SYMLIN(R),(pramlintide acetate) injection. ... dosing to improve mealtime glucose control. ...
... from Positive VENT Trial Presented at ERS 17th ... 1 Emphasys Medical Inc.,today announced the submission ... Food and Drug Administration (FDA) requesting regulatory,approval to ... in,the United States. The Zephyr EBV is a ...
... period of time after leaving the foster care system ... those with stable housing situations, according to a report ... Adolescent Medicine, one of the JAMA/Archives journals. Youth who ... leaving the foster care system appear to have more ...
... Behavioral,Health System, a UHS facility, has announced the ... teens in crisis. The new treatment,center is associated ... http://www.highlandsbhs.com ) in Littleton, Colo. Highlands Behavioral ... of Excellence represents an expansion of the Adolescent,Unit ...
Cached Medicine News:Health News:Kerry Extends, Improves Small Business Innovation Program 2Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 3Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 4Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 3Health News:Poor health care access common among youth leaving foster system 2Health News:Poor health care access common among youth leaving foster system 3Health News:New Denver Area Program Developed For Teens in Crisis 2
... advancement in supralaryngeal airway management., ,The CobraPLA ... the hypopharynx where it abuts the structure of ... head design of the distal end of the ... epiglottis out of the way, facilitating ventilation through ...
Robertazzi Amber Latex Free Nasal Airways are manufactured from natural amber latex. Soft, flexible maximizing comfort....
Robertazzi Latex Free Nasal Airways are manufactured from soft neoprene and have smooth beveled tip for gentle insertion....
Extra soft for patient comfort., ,The Argyle® Nasopharyngeal Airway provides an open airway to make suctioning and bronchoscopy easier, safer, and less traumatic....
Medicine Products: